Pathway Financial Advisers’s AbbVie ABBV Stock Holding History

Pathway Financial Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.45M	Buy	34,237 +686	+2%	+$152K	2.11%	6
2025 Q4	$7.67M	Sell	33,551 -25	-0.1%	-$5.7K	2.22%	5
2025 Q3	$7.73M	Buy	33,576 +1,082	+3%	+$220K	2.26%	4
2025 Q2	$6.03M	Buy	32,494 +379	+1%	+$70.4K	1.95%	7
2025 Q1	$6.73M	Sell	32,115 -601	-2%	-$117K	2.31%	4
2024 Q4	$5.81M	Buy	32,716 +37	+0.1%	+$6.8K	1.95%	7
2024 Q3	$6.45M	Sell	32,679 -238	-0.7%	-$44.4K	2.92%	2
2024 Q2	$5.62M	Buy	32,917 +520	+2%	+$86.1K	2.01%	7
2024 Q1	$5.9M	Sell	32,397 -1,710	-5%	-$295K	2.12%	6
2023 Q4	$5.29M	Buy	34,107 +17	+0%	+$2.48K	2.01%	7
2023 Q3	$5.08M	Buy	+34,090	New	+$5M	2.1%	6
2023 Q1	$5.42M	Sell	34,019 -4,126	-11%	-$631K	2.18%	4
2022 Q4	$6.16M	Buy	+38,145	New	+$5.85M	2.5%	1

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pathway Financial Advisers's ABBV Position: Q1 2026 in Review

Pathway Financial Advisers increased its AbbVie (ABBV) stake by 2% in Q1 2026, buying an estimated $152K and bringing the position to 34,237 shares worth $7.45M. The position accounts for 2.11% of the portfolio, ranked #6.

Pathway Financial Advisers first reported a position in ABBV in Q4 2022 and has held it in 13 quarters since. The position peaked at $7.73M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Pathway Financial Advisers held 34,237 shares of AbbVie worth $7.45M as of Q1 2026.
Pathway Financial Advisers bought 686 AbbVie shares in Q1 2026, an estimated $152K.
AbbVie made up 2.11% of Pathway Financial Advisers's portfolio in Q1 2026, its #6 holding.
Pathway Financial Advisers first reported a position in AbbVie in Q4 2022 and has held it in 13 quarters since.
Pathway Financial Advisers's AbbVie position peaked at $7.73M in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Pathway Financial Advisers's 13F filing for Q1 2026, filed 23 Apr 2026.